
LSD1-IN-30
CAS No. 1289575-45-6
LSD1-IN-30( —— )
Catalog No. M37358 CAS No. 1289575-45-6
LSD1-IN-30 is a lysine-specific demethylase 1 (LSD1) inhibitor with anticancer activity for the study of small cell lung cancer and acute myeloid leukemia.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 179 | Get Quote |
![]() ![]() |
5MG | 282 | Get Quote |
![]() ![]() |
10MG | 451 | Get Quote |
![]() ![]() |
25MG | 877 | Get Quote |
![]() ![]() |
50MG | 1408 | Get Quote |
![]() ![]() |
100MG | 2205 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameLSD1-IN-30
-
NoteResearch use only, not for human use.
-
Brief DescriptionLSD1-IN-30 is a lysine-specific demethylase 1 (LSD1) inhibitor with anticancer activity for the study of small cell lung cancer and acute myeloid leukemia.
-
DescriptionLSD1-IN-30 (compound 3) is a potent inhibitor of lysine-specific demethylase 1 (LSD1), with the IC50 value of 0.291 μM.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetHistone Demethylase
-
RecptorHistone Demethylase
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1289575-45-6
-
Formula Weight270.28
-
Molecular FormulaC15H14N2O3
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (369.99 mM; Ultrasonic )
-
SMILESC(=N\NC(=O)C1=CC=C(O)C=C1)(\C)/C2=C(O)C=CC=C2
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Venkataswamy Sorna, et al. High-Throughput Virtual Screening Identifies Novel N′?(1-Phenylethylidene)-benzohydrazides as Potent, Specific, and Reversible LSD1 Inhibitors. J Med Chem. 2013 Dec 12;56(23):9496-508.?
molnova catalog



related products
-
SD49-7
SD49-7 is an inhibitor of histone lysine demethylase 4 (KDM4) with an IC50 of 0.19 μM.
-
E67-2
E67-2 is a potent and selective inhibitor of H3K9 Jumonji demethylase KIAA1718 (KDM7A) with IC50 of 3.4 uM.
-
KDM5-IN-48
A potent, selective and orally bioavailable KDM5 inhibitor with biochemical IC50 of 15.1, 4.7 and 65.5 nM for KDM5A, KDM5B and KDM5C, respectively.